Your AI-Trained Oncology Knowledge Connection!

Updates in HER2+ Early and Metastatic Breast Cancer : Episode 7

Video

February 13, 2023

Clinical Data Updates on Adjuvant Pertuzumab/Trastuzumab for HER2+ Early Breast Cancer

Author(s):

Joyce O’Shaughnessy, MD,Virginia Borges, MD

A review of recently reported data on the use of adjuvant pertuzumab/trastuzumab for the treatment of HER2+ early breast cancer, including data from the APHINITY and PHranceSCa trials.

EP: 1.Incidence and Typical Prognosis of HER2+ Early Breast Cancer

EP: 2.Neoadjuvant Treatment of HER2+ Early Breast Cancer

EP: 3.De-Escalation Approaches in Patients with HER2+ Early Breast Cancer

EP: 4.Subcutaneous vs Intravenous Pertuzumab/Trastuzumab for Treatment of HER2+ Early Breast Cancer

EP: 5.Factors Informing Adjuvant Treatment Selection in HER2+ Early Breast Cancer

EP: 6.Expert Perspectives on Clinical Experience with Ado-Trastuzumab Emtansine (T-DM1)

Now Viewing

EP: 7.Clinical Data Updates on Adjuvant Pertuzumab/Trastuzumab for HER2+ Early Breast Cancer

EP: 8.Extended Adjuvant Neratinib Therapy for Patients with HER2+ Early Breast Cancer

EP: 9.Data Updates in Adjuvant HER2+ Early Breast Cancer from SABCS 2022

EP: 10.HER2+ mBC: First-Line Treatment Regimens

EP: 11.Second-Line Treatment of HER2+ mBC and Recent Data Updates

EP: 12.Options for Third- and Further-Line Treatment of HER2+ mBC

EP: 13.Use of MRI for Surveillance of Brain Metastases in Patients with HER2+ mBC

EP: 14.Emerging Data and Investigational Agents in HER2+ mBC

EP: 15.Unmet Needs and the Future of HER2+ Breast Cancer Treatment

Stay up to date on the most recent and practice-changing oncology data

Subscribe Now!

Latest CME

View All

Video

Community Oncology Connections™: Contextualizing Novel Immunotherapy for Advanced Melanoma – How Do TIL Therapies Fit into Practice? | North Carolina

May 2nd 2025 - Jun 7th 2025

online-activity

Video

Community Oncology Connections™: Navigating Early-Stage HR+/HER2- Breast Cancer – Clinical Developments and Innovative Treatments | Kansas

May 1st 2025 - Jun 6th 2025

online-activity

Video

From Bench to Bedside: Paradigm Shifts in HER2+ Metastatic BTC Treatment

May 1st 2025 - May 2nd 2026

online-activity

Latest Conference Coverage

Insights From Liso-cel Combined With Ibr for R/RCLL/SLL: Primary Results From the Open-Label, Phase 1/2 Transcend CLL 004 Study

Overview of the Fixed-Duration Epcoritamab + R-Mini-CHOP in Patients With Previously Untreated DLBCL Ineligible for Full-Dose R-CHOP: Updated Results from Arm 8 of the Epcore NHL-2 Trial

Ultra-Low PSA Response With Darolutamide/ADT Correlates With Better Outcomes in mHSPC

Botensilimab Plus Balstilimab Elicits Durable Responses in Treatment-Refractory HCC

View More Latest Conference Coverage

Advertise

About OncLive

Editorial Board

MJH Life Sciences brands

Privacy

Terms & Conditions

Do Not Sell My Information

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

Clinical Data Updates on Adjuvant Pertuzumab/Trastuzumab for HER2+ Early Breast Cancer

EP: 1.Incidence and Typical Prognosis of HER2+ Early Breast Cancer

EP: 2.Neoadjuvant Treatment of HER2+ Early Breast Cancer

EP: 3.De-Escalation Approaches in Patients with HER2+ Early Breast Cancer

EP: 4.Subcutaneous vs Intravenous Pertuzumab/Trastuzumab for Treatment of HER2+ Early Breast Cancer

EP: 5.Factors Informing Adjuvant Treatment Selection in HER2+ Early Breast Cancer

EP: 6.Expert Perspectives on Clinical Experience with Ado-Trastuzumab Emtansine (T-DM1)

EP: 7.Clinical Data Updates on Adjuvant Pertuzumab/Trastuzumab for HER2+ Early Breast Cancer

EP: 8.Extended Adjuvant Neratinib Therapy for Patients with HER2+ Early Breast Cancer

EP: 9.Data Updates in Adjuvant HER2+ Early Breast Cancer from SABCS 2022

EP: 10.HER2+ mBC: First-Line Treatment Regimens

EP: 11.Second-Line Treatment of HER2+ mBC and Recent Data Updates

EP: 12.Options for Third- and Further-Line Treatment of HER2+ mBC

EP: 13.Use of MRI for Surveillance of Brain Metastases in Patients with HER2+ mBC

EP: 14.Emerging Data and Investigational Agents in HER2+ mBC

EP: 15.Unmet Needs and the Future of HER2+ Breast Cancer Treatment

Newsletter

Latest CME

From Bench to Bedside: Paradigm Shifts in HER2+ Metastatic BTC Treatment

Community Practice Connections™: Shaping Surgical Pathways: Revolutionizing Breast Cancer Care With Genetic Testing and Targeted Treatment

Community Practice Connections™: Tailored Treatment Approaches for Older Patients With Advanced HR+/HER2– Breast Cancer

Community Oncology Connections™: Contextualizing Novel Immunotherapy for Advanced Melanoma – How Do TIL Therapies Fit into Practice? | North Carolina

Community Oncology Connections™: Navigating Early-Stage HR+/HER2- Breast Cancer – Clinical Developments and Innovative Treatments | Kansas

From Bench to Bedside: Paradigm Shifts in HER2+ Metastatic BTC Treatment

Community Practice Connections™: Shaping Surgical Pathways: Revolutionizing Breast Cancer Care With Genetic Testing and Targeted Treatment

Community Practice Connections™: Tailored Treatment Approaches for Older Patients With Advanced HR+/HER2– Breast Cancer

Community Oncology Connections™: Contextualizing Novel Immunotherapy for Advanced Melanoma – How Do TIL Therapies Fit into Practice? | North Carolina

Community Oncology Connections™: Navigating Early-Stage HR+/HER2- Breast Cancer – Clinical Developments and Innovative Treatments | Kansas

From Bench to Bedside: Paradigm Shifts in HER2+ Metastatic BTC Treatment

Community Practice Connections™: Shaping Surgical Pathways: Revolutionizing Breast Cancer Care With Genetic Testing and Targeted Treatment

Community Practice Connections™: Tailored Treatment Approaches for Older Patients With Advanced HR+/HER2– Breast Cancer

Latest Conference Coverage